Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers
Interim assessment anticipated by end of 2020 YAVNE, Israel , Dec. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the “Company”) (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the
View HTML
Toggle Summary MediWound Reports Third Quarter 2019 Financial Results
Total revenues of $5.1 million , driven primarily by revenues from development services Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing in the second quarter of 2020 Expected to initiate patient treatment in EscharEx® U.S.
View HTML
Toggle Summary MediWound to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 14
YAVNE, Israel , Nov. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third
View HTML
Toggle Summary Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
CAMBRIDGE, Mass. and YAVNE, Israel, October 2 , 2019 – Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thickness burns in the U.S.
View HTML
Toggle Summary NexoBrid® Highlighted in 39 Presentations at the 18th European Burns Association Congress in Helsinki
YAVNE, Israel , Sept. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound care management, today announced a significant presence at the 18 th European Burns
View HTML
Toggle Summary MediWound Reports Second Quarter 2019 Financial Results
Total revenues of $20.7 million , driven primarily by the upfront payment from Vericel for NexoBrid ® license agreement BARDA committed additional $21 million to fund NexoBrid ® expanded access treatment protocol Confirmed BLA submission plans in a pre-BLA meeting with FDA Company to initiate an
View HTML
Toggle Summary MediWound to Report Second Quarter 2019 Financial Results and Host a Conference Call and Webcast on August 13
YAVNE, Israel , Aug. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second
View HTML
Toggle Summary MediWound Launches EscharEx® U.S. Clinical Development Program
Company’s primary focus turns to EscharEx following its successful collaboration for NexoBrid Company to initiate an adaptive comprehensive adequately controlled study in 4Q 2019 Company to host Analyst Day today, July 22 , in New York, NY YAVNE, Israel , July 22, 2019 (GLOBE NEWSWIRE) -- MediWound
View HTML
Toggle Summary MediWound to Host Analyst Day on its Innovative Product EscharEx® for Debridement of Chronic Wounds
YAVNE, Israel , July 16, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wounds on Monday,
View HTML
Toggle Summary MediWound Appoints Mr. Boaz Gur-Lavie as Chief Financial Officer
YAVNE, Israel , June 11, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr.
View HTML